Sean F. Moran sold $221k of CRBP
Chief Financial Officer at Corbus Pharmaceuticals Holdings, Inc.. 12,981 shares at an average of $17.02, traded Oct 24, 2025, filed Oct 27, 2025.
Score components
- +22RoleCFO
- +12Trade size$221k at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-251635, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 24, 2025 | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +12,981 | $4.26 | $55k | 86,294 | Oct 27, 2025 |
| Oct 24, 2025 | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -12,981 | $17.02 | $221k | 73,313 | Oct 27, 2025 |
| Oct 24, 2025 | MOption exercise Stock options (right to buy)derivative10b5-1 | -12,981 | $0.00 | $0 | 10,386 | Oct 27, 2025 |
Related signals
Other insiders at Corbus Pharmaceuticals Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | Yong Ben director | $16k 2,000 shares | -18% | |
| 27Weak | CRBPsell Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP owner | $344k 30,029 shares | -1% | |
| 27Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $471k 27,633 shares | -18% | |
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | Anne Altmeyer director | $22k 1,060 shares | -15% | |
| 23Weak | Corbus Pharmaceuticals Holdings, Inc. | Anne Altmeyer director | $10k 1,392 shares | -50% | |
| 23Weak | Corbus Pharmaceuticals Holdings, Inc. | John Kenneth Jenkins director | $20k 2,783 shares | -99% | |
| 21Weak | CRBPsell Corbus Pharmaceuticals Holdings, Inc. | Dominic Smethurst Chief Medical Officer | $43k 6,393 shares | -8% | |
| 20Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $62k 7,134 shares | -5% | |
| 10Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $24k 2,792 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.